Ensign Peak Advisors’s aTyr Pharma ATYR Stock Holding History

Ensign Peak Advisors’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-414,732	Closed	-$299K	–	1737
2025 Q3	$299K	Buy	414,732 +179,057	+76%	+$811K	﹤0.01%	1573
2025 Q2	$1.19M	Buy	+235,675	New	+$927K	﹤0.01%	1138
2023 Q2	–	Sell	-37,884	Closed	-$79.6K	–	1777
2023 Q1	$79.6K	Hold	37,884	–	–	﹤0.01%	1759
2022 Q4	$83K	Hold	37,884	–	–	﹤0.01%	1770
2022 Q3	$114K	Hold	37,884	–	–	﹤0.01%	2057
2022 Q2	$107K	Hold	37,884	–	–	﹤0.01%	1949
2022 Q1	$203K	Hold	37,884	–	–	﹤0.01%	1874
2021 Q4	$283K	Hold	37,884	–	–	﹤0.01%	1835
2021 Q3	$344K	Hold	37,884	–	–	﹤0.01%	1694
2021 Q2	$185K	Hold	37,884	–	–	﹤0.01%	1733
2021 Q1	$169K	Hold	37,884	–	–	﹤0.01%	1746
2020 Q4	$147K	Hold	37,884	–	–	﹤0.01%	1750
2020 Q3	$122K	Hold	37,884	–	–	﹤0.01%	1698
2020 Q2	$168K	Hold	37,884	–	–	﹤0.01%	1598
2020 Q1	$106K	Hold	37,884	–	–	﹤0.01%	1576
2019 Q4	$158K	Buy	+37,884	New	+$146K	﹤0.01%	1628

Other funds holding ATYR

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ensign Peak Advisors's ATYR Position: Q4 2025 in Review

Ensign Peak Advisors sold out of aTyr Pharma (ATYR) in Q4 2025, closing a stake of 414,732 shares — an estimated $299K sold.

Ensign Peak Advisors first reported a position in ATYR in Q4 2019 and held it in 16 quarters. The position peaked at $1.19M in Q2 2025. 84 funds tracked by Wall St. Rank hold ATYR as of Q4 2025.

Ensign Peak Advisors reported no remaining aTyr Pharma position as of Q4 2025 after selling out during the quarter.
Ensign Peak Advisors sold 414,732 aTyr Pharma shares in Q4 2025, an estimated $299K.
Ensign Peak Advisors first reported a position in aTyr Pharma in Q4 2019 and held it in 16 quarters.
Ensign Peak Advisors's aTyr Pharma position peaked at $1.19M in Q2 2025.
84 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2025.

Based on Ensign Peak Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.